Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a…

Overview of attention for article published in BMC Cancer, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 17 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 34 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 19 X posts from 17 X users, with an upper bound of 63,955 followers.

RT @PauloBergerot: Interesting findings from Real-world, observational study Abi vs Cabazi after PD w docetax ⬆️ use of abi ‼️Post hoc adj…

08 Sep 2019

Reply Repost Favourite

RT @PauloBergerot: Interesting findings from Real-world, observational study Abi vs Cabazi after PD w docetax ⬆️ use of abi ‼️Post hoc adj…

08 Sep 2019

Reply Repost Favourite

Thanks @PauloBergerot

08 Sep 2019

Reply Repost Favourite

Interesting findings from Real-world, observational study Abi vs Cabazi after PD w docetax ⬆️ use of abi ‼️Post hoc adjusted analysis for potential confounders showed no differences in PFS or OS between them ‼️ @docjavip #ProstateCancer @BioMedCentral

08 Sep 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.